16 March 2023
SHARE NOW
Cell Therapy
Collaborations, Mergers & Acquisitions
Gene Therapy
GMP
Logistics
Patient Access & Engagement
Regulatory & Standards
Scaling Up
Strategy
Supply Chain
Rupa Pike, Senior Director of Technical Affairs, Advanced Therapies, Thermo Fisher Scientific, joined us live at Advanced Therapies Week 2023 to discuss and shed some light on the current autologous vs allogeneic cell therapy landscape.
Discussing arguably one of the biggest debates in cell and gene therapy right now, autologous vs allogeneic, Rupa first takes a broad look at the market trends we are seeing in CGT development and manufacturing, before zooming in on the CDMO preparations, as well as supply chain and logistical considerations required for each method.
Rupa then goes on to consider the importance of mitigating manufacture risks in the unique regulatory environment that advanced therapies are developed and commercialized in, noting the benefits of collaboration to novel therapy delivery.
This interview has been produced in partnership with Thermo Fisher Scientific and was recorded at Advanced Therapies Week 2023.
 |
 |
More like this
Must-See Sessions at Advanced Therapies Week 2025: Ry Leahy, Head of Content, Phacilitate
Cell and gene therapies are set to revolutionize the future of medicine, but one of the major hurdles is the production of good quality cells cost-effectively and at scale
10 January 2025
ATW Speaker Patrick M Gailliot Previews Event and Discusses His Role in Autologous Cell and Gene Therapies
We caught up with Patrick M Gailliot, Sr. Director, Patient Operations at Abeona Therapeutics, to talk to him about why his work gives him so much joy, preview his session at Advanced Therapies Week in Dallas, and explain the value he gets from the event.
26 November 2024
Texas Cell and Gene Manufacturing Landscape
Ahead of Advanced Therapies Week 2025 in Dallas, we take a look at the Texas cell and gene manufacturing landscape.
19 November 2024
